

27 July 2010

Original: English

Expert group on data collection

Vienna, 11-13 October 2010

Item 3 of the provisional agenda*

**Finalization of the content and structure of a revised,
simple and efficient reporting system**

**Revised draft annual report questionnaire:
Part Three. Extent, patterns and trends in drug use**

Note by the Secretariat

* UNODC/CND/EG.1/2010/9.



Revised draft annual report questionnaire

Part Three. Extent, patterns and trends in drug use

Report of the Government of _____

Reporting year _____

Completed on (date) _____

Please return the completed questionnaire to: arq@unodc.org

The completed revised draft annual report questionnaire is due on: [date].

For technical support, contact:

	Telephone	Fax	E-mail
UNODC Vienna	1 800 123 456	1 800 654 321	arqhelp@unodc.org
Regional offices:			
[list]			

Note

This is a printable version of the revised draft annual report questionnaire, which is in the form of an Excel spreadsheet and is designed to be completed electronically. In this printable version, definitions of key terms used in the questionnaire are provided in the footnotes, whenever relevant; in the electronic version, these definitions (and additional instructions) are repeated throughout the questionnaire through the “Comments” function in Excel. The Excel spreadsheet also uses drop-down lists for some questions, allowing respondents to simply select from a list the answer that is most appropriate for their country.

Instructions

The revised draft annual report questionnaire consists of the following four parts:

Part One. Legislative and institutional framework

Part Two. Comprehensive approach to drug demand and supply reduction

Part Three. Extent, patterns and trends in drug use

Part Four. Extent, patterns and trends in drug cultivation, manufacture and trafficking

This is part three of the revised draft annual report questionnaire.

Respondents are asked to complete all questions. Where no data are available, this should be indicated by inserting two dashes (--) or writing "don't know" in the appropriate cell. All questions refer to the reporting year, unless otherwise indicated.

Respondents

All countries are invited to identify a single focal point for reporting data on drugs. In exceptional and duly justified cases, respondents may identify additional technical contacts who may contribute to completing the questionnaire, indicating, if possible, which questions they contributed to.

Metadata

Respondents may refer to multiple sources in completing the revised draft annual report questionnaire. These sources may include published reports and/or data sets not in the public domain, including routinely collected data from treatment, law enforcement or other agencies. All sources referred to during the completion of the questionnaire should be listed in the section on metadata, which can be found at the end of each section of the questionnaire. This information helps UNODC to understand the information provided.

About the questions

In recognition of the fact that not all countries have detailed data on all of the topics covered in the questionnaire, part three of the revised draft annual report questionnaire asks for quantitative information and information about experts' perceptions of the situation and trends.

Quantitative data or estimates

The questions ask for quantitative data or estimates. The revised draft annual report questionnaire includes standardized response categories but, should the data available not conform to those categories, they can still be included. Simply indicate the categories used (e.g. age range, drug category) in the space provided. Quantitative data or estimates should be provided for the reporting year. Where this is not possible, please include the most appropriate recent figures available. The year in which the data were collected should always be specified. If national data or estimates are not available, data or an estimate for a part of the country or for a sub-group of the population can be indicated. If more than one such partial dataset

or estimate is available, the data or estimate that is believed to be the best alternative for recent national data or estimates should be used. In such cases, the geographical or population coverage of the data or estimate should be specified as simply and as explicitly as possible; similarly, the size of the population should also be specified, if relevant.

Several questions relate to classes or types of drugs. Whenever applicable, it is important that the information requested relate to individual drugs. Although care has been taken to include all major drugs, the pre-coded lists might not fully match the needs of every country. Therefore, in each list the opportunity has been provided to add other classes or types of drugs. These open categories can also be used to insert alternative groups of drugs. For example: some questions list “heroin” and “other illicit opioids”; if the only information available is on opioids in general (no types are specified), “any opioids” should be listed under “other drugs”.

Technical notes

Some technical terms are explained below.

Technical terms

Incidence	The proportion of individuals in a specific population who are newly diagnosed as having a specific health condition (e.g. HIV) or problem in a given time period (e.g. one year). For example: 2 per cent of persons aged 34 years and older residing in London reported having used marijuana for the first time in 2000.
Prevalence	<p>The proportion of individuals in a specific population with a given condition (e.g. HIV) or engaging in a particular type of behaviour (e.g. injecting drug use) in a given period. For example: 10 per cent of persons aged 34 years and older residing in London reported having used marijuana in 2000.</p> <p>The term “lifetime prevalence of drug use” refers to the proportion of individuals who have used a drug at least once in their lifetime.</p> <p>The term “annual prevalence of drug use” refers to the proportion of individuals who used a drug at least once in the 12 months prior to the survey.</p> <p>The term “past 30-day prevalence of drug use” refers to the proportion of individuals who used a drug at least once in the 30 days prior to the survey.</p>
Reference population	The entire population to which an estimate applies.
Reporting year	The year _____ (to be indicated each year).

Classes and types of drugs under international control (narcotic drugs and psychotropic substances)

Listed below are the classes and types of drugs included in the revised draft annual report questionnaire. In some cases, examples of particular drug types are provided, but the lists of these examples are not exhaustive.

Class of drug	Type of drug
Any illicit drug	All illicit drugs and substances under international control, including prescription opioids, stimulants, tranquilizers and sedatives, that are misused or used for non-therapeutic purposes. Alcohol and tobacco are not included.
Cannabis	Marijuana (herb) Hashish (resin)
Opioids	Heroin Opium Prescription opioids such as buprenorphine (Suboxone, Subutex), codeine, dextropropoxyphene, fentanyl, oxycodone (Oxycontin) hydrocodone (Vicodin), hydromorphone, methadone, morphine and pethidine Other illicit opioids (e.g. “homebake”)
Cocaine	Powder (salt) “Crack” Other types of cocaine, such as coca paste, cocaine paste, cocaine base, <i>basuco</i> , <i>paco</i> and <i>merla</i>
Amphetamine-type stimulants	Amphetamine Methamphetamine Prescription stimulants such as amfepramone, fenetylline, methylphenidate (Ritalin), pemoline, phenmetrazine, phentermine and dextroamphetamine “Ecstasy”-type substances (e.g. MDA, MDE/MDEA, MDMA) ¹ Other illicit amphetamine-type stimulants (e.g. Captagon, methcathinone, 4-MTA, 2C-B, MDBD)
Sedatives and tranquilizers (for non-therapeutic/non-prescription use)	Benzodiazepines: alprazolam (Xanax), clonazepam (Rivotril), diazepam (Valium), temazepam and flunitrazepam (Rohypnol) Barbiturates: allobarbitol, barbital, Phenobarbital, pentobarbital, secbutabarbitol etc. Other sedative hypnotics: meprobamate, methaqualone (Mandrax) and zolpidem

¹ MDA=methylenedioxyamphetamine; MDEA=3,4-methylenedioxyethylamphetamine; MDMA=methylenedioxymethamphetamine.

Hallucinogens	Lysergic acid diethylamide (LSD) Other hallucinogens (e.g. phencyclidine (PCP), mushrooms with psychoactive properties, tryptamines)
Solvents and inhalants	
Other drugs such as those under national but not international control	Including <i>gamma</i> -butyrolactone (GBL), khat, piperazines (e.g. <i>N</i> -benzylpiperazine (BZP)), tramadol and ketamine

Respondents

Instructions

Provide details on the focal point charged with reporting drug data for your country. In the exceptional cases in which technical contacts have been identified, you may wish to list them in the table entitled “additional technical contacts”, indicating, if possible, which questions they have contributed to.

Focal point

Name	Position	Agency	Telephone	Fax	E-mail

Additional technical contacts (optional)

	Name	Position	Agency	Telephone	Fax	E-mail	Questions contributed to
<i>Example</i>	<i>Mr. John Smith</i>	<i>Chief Statistician</i>	<i>Office of Drug Control</i>	<i>+44 221 6573</i>	<i>+44 221 6001</i>	<i>j.smith@odc.gov</i>	<i>6-9 and 10-13</i>
Contributor 1							
Contributor 2							
Contributor 3							
Contributor 4							
Contributor 5							

Prevalence of drug use: general population

Class and type of drugs	Question		
	1	2	3
	Has this drug been used in your country in the reporting year?	Rank these classes of drugs ^a in order of prevalence of use in the reporting year	Rank the drug types within each class of drugs in order of prevalence of use in the reporting year
	No	Yes	Don't know
Cannabis			
Marijuana (herb)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Hashish (resin)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other types of cannabis (specify) _____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Opioids			
Opium	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Heroin	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Prescription opioids ^b (non-prescription/non-therapeutic use)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other illicit opioids (specify) _____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Cocaine			
Powder (salt)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
“Crack”	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other types of cocaine (specify) ^c _____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Amphetamine-type stimulants			
Amphetamine	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Methamphetamine	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
“Ecstasy”-type substances	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Prescription stimulants ^d (non-prescription/non-therapeutic use)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other illicit amphetamine-type stimulants (specify) ^e _____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Tranquilizers and sedatives (non-prescription/non-therapeutic use)			
Benzodiazepines ^f	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Barbiturates ^g	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other sedative hypnotics (specify) ^h _____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Hallucinogens			
LSD	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other hallucinogens (specify) _____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Solvents and inhalants	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Other drugs such as those under national but not international control (specify)ⁱ

	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

^a For the purpose of this questionnaire, alcohol and tobacco are not included.

^b Prescription opioids may include preparations containing buprenorphine, codeine, dextropropoxyphene, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone and pethidine.

^c Other types of cocaine include coca paste and cocaine paste, cocaine base, *basuco*, *paco*, *merla* etc. (based on the Multilateral Evaluation Mechanism of the Inter-American Drug Abuse Control Commission (CICAD)).

^d Prescription stimulants may include preparations containing amfepramone, fenetylline, methylphenidate, pemoline, phenmetrazine and phentermine.

^e Other illicit amphetamine-type stimulants may include preparations such as Captagon, methcathinone, 4-MTA, 2C-B, MDBD etc.

^f Benzodiazepines may include preparations such as alprazolam, clonazepam, diazepam, temazepam and flunitrazepam (Rohypnol).

^g Barbiturates may include preparations containing allobarbitol, barbitol, phenobarbital, pentobarbital, secbutabarbitol etc.

^h Other sedative hypnotics may include preparations containing meprobamate, methaqualone, zolpidem etc.

ⁱ Other drugs such as those under national but not international control may include substances such as *gamma*-butyrolactone (GBL), khat, piperazines (e.g. *N*-benzylpiperazine), tramadol and ketamine.

Class and type of drugs	Question													
	4							5						
	How much has the prevalence of use of each class of drugs changed in the reporting year? ^{a, b}							How much has the prevalence of use of each type of drug changed in the reporting year? ^{a, b}						
	Large increase	Some increase	Stable	Some decrease	Large decrease	Don't know		Large increase	Some increase	Stable	Some decrease	Large decrease	Don't know	
Cannabis	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Marijuana (herb)								<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Hashish (resin)								<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Other types of cannabis (specify)								<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Opioids	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Opium								<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Heroin								<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Prescription opioids ^c								<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
(non-prescription/ non-therapeutic use)								<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Other illicit opioids (specify)								<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Cocaine	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Powder (salt)								<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
"Crack"								<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Other types of cocaine (specify) ^d								<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Amphetamine-type stimulants	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Amphetamine								<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Methamphetamine								<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
"Ecstasy"-type substances								<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Prescription stimulants ^e								<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Other illicit amphetamine-type stimulants (specify) ^f	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Tranquilizers and sedatives (non-prescription/non-therapeutic use)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Benzodiazepines ^g	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Barbiturates ^h	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other sedative hypnotics (specify) ⁱ	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Hallucinogens	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
LSD	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other hallucinogens (specify)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Solvents and inhalants	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other drugs such as those under national but not international control (specify)^j	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

^a "Stable" refers to an estimated variation of under 5 per cent; "some increase" and "some decrease" refer to an estimated variation of between 5 and 10 per cent; "large increase" and "large decrease" refer to an estimated variation of more than 10 per cent.

^b The term "change in prevalence" refers to the change observed since the last reporting year. For instance, if the prevalence was estimated at 3.6 per cent in 2006 and changed to 3.9 per cent in 2007, the change over the reporting year would be of around 8 per cent. Such a change could be characterized as representing "some increase" in prevalence.

^c Prescription opioids may include preparations containing buprenorphine, codeine, dextropropoxyphene, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone and pethidine.

^d Other types of cocaine include coca paste and cocaine paste, cocaine base, *basuco*, *paco*, *merla* etc. (based on the Multilateral Evaluation Mechanism of the Inter-American Drug Abuse Control Commission (CICAD)).

^e Prescription stimulants may include preparations containing amfepramone, fenetylline, methylphenidate, pemoline, phenmetrazine and phentermine.

^f Other illicit amphetamine-type stimulants may include preparations such as Captagon, methcathinone, 4-MTA, 2C-B, MDBD etc.

^g Benzodiazepines may include preparations such as alprazolam, clonazepam, diazepam, temazepam and flunitrazepam (Rohypnol).

^h Barbiturates may include preparations containing allobarbitol, barbitol, phenobarbital, pentobarbital, secbutabarbitol etc.

ⁱ Other sedative hypnotics may include preparations containing meprobamate, methaqualone, zolpidem etc.

^j Other drugs such as those under national but not international control may include substances such as *gamma*-butyrolactone (GBL), khat, piperazines (e.g. *N*-benzylpiperazine), tramadol and ketamine.

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

Prevalence/number of drug users: general population

6. Do you have data on the prevalence or number of drug users among the general population?

- ☐ No (go to question 12)
☐ Yes, for the whole population
☐ Yes, for part of the population

7. (a) In which year were the data collected? _____.

(b) Which part of the country or the population is covered by the data? _____.

(c) What is the size of general population to which the estimates apply? _____.

(d) What is the source of the data you are reporting?

- ☐ General population survey
☐ Indirect estimate
☐ Treatment register
☐ Register of drug users _____
☐ Other (specify: _____)

Question										
8				9				10		
What is the lifetime prevalence among the general population?				What is the annual prevalence among the general population?				What is the past 30-day prevalence among the general population?		
Preferred age range: 15-64 years Age range used: _____										
Class and type of drugs	Male (%)	Female (%)	Total (%)	Male (%)	Female (%)	Total (%)	Estimated number of users	Male (%)	Female (%)	Total (%)
Any illicit drug^a										
Cannabis										
Marijuana (herb)										
Hashish (resin)										
Other types of cannabis (specify) _____										

Opioids

Opium

Heroin

Prescription opioids^b(non-prescription/
non-therapeutic use)

Other illicit opioids (specify)

Cocaine

Powder (salt)

"Crack"

Other types of cocaine
(specify)^c

Amphetamine-type stimulants

Amphetamine

Methamphetamine

"Ecstasy"-type substances

Prescription stimulants^d(non-prescription/
non-therapeutic use)Other illicit stimulants
(specify)^e

Tranquilizers and sedatives(non-prescription/
non-therapeutic use)Benzodiazepines^fBarbiturates^gOther (specify)^h

Hallucinogens

LSD

Other hallucinogens (specify)

Solvents and inhalants

--	--	--	--	--	--	--	--	--	--

**Other drugs such as those
under national but not
international control (specify)ⁱ**

- ^a Excluding alcohol and tobacco, but including controlled substances that are misused or used for non-therapeutic purposes.
- ^b Prescription opioids may include preparations containing buprenorphine, codeine, dextropropoxyphene, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone and pethidine.
- ^c Other types of cocaine include coca paste and cocaine paste, cocaine base, *basuco*, *paco*, *merla* etc. (based on the Multilateral Evaluation Mechanism of the Inter-American Drug Abuse Control Commission (CICAD)).
- ^d Prescription stimulants may include preparations containing amfepramone, fenetylline, methylphenidate, pemoline, phenmetrazine and phentermine.
- ^e Other illicit amphetamine-type stimulants may include preparations such as Captagon, methcathinone, 4-MTA, 2C-B, MDBD etc.
- ^f Benzodiazepines may include preparations such as alprazolam, clonazepam, diazepam, temazepam and flunitrazepam (Rohypnol).
- ^g Barbiturates may include preparations containing allobarbitol, barbitol, phenobarbital, pentobarbital, secbutabarbitol etc.
- ^h Other sedative hypnotics may include preparations containing meprobamate, methaqualone, zolpidem etc.
- ⁱ Other drugs such as those under national but not international control may include substances such as *gamma*-butyrolactone (GBL), khat, piperazines (e.g. *N*-benzylpiperazine), tramadol and ketamine.

Question 11

If your country maintains a register of drug users, what is the estimated number of drug users registered for each of the following drugs?

Class of drugs	Number of registered drug users
Any illicit drug ^a	
Cannabis	
Opioids	
Cocaine	
Amphetamine-type stimulants	
Tranquilizers and sedatives	
Hallucinogens	
Solvents and inhalants	
Other drugs such as those under national but not international control (specify)	

- ^a Excluding alcohol and tobacco, but including controlled substances that are misused or used for non-therapeutic purposes.

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

Prevalence/number of drug users: youth

12. Do you have data on the prevalence or number of drug users among youth?

- ☐ No (go to question 17)
☐ Yes, for the whole population
☐ Yes, for part of the population

13. (a) In which year were the data collected? _____.

(b) Which part of the country or sub-group of the population is covered by the data? _____.

(c) What is the size of youth population to which the estimates apply? _____.

(d) What is the source of the data you are reporting?

- ☐ School survey
☐ General population survey
☐ Indirect estimate
☐ Treatment or other register of drug users
☐ Other (specify: _____)

Question									
14				15			16		
What is the lifetime prevalence among youth?				What is the annual prevalence among youth?			What is the past 30-day prevalence among youth?		
Preferred age range: 15-16 years Age range used: _____									
Class and type of drugs									
	Male (%)	Female (%)	Total (%)	Male (%)	Female (%)	Total (%)	Male (%)	Female (%)	Total (%)
Any illicit drug^a									
Cannabis									
Marijuana (herb)									
Hashish (resin)									
Other types of cannabis (specify)									
Opioids									
Opium									
Heroin									
Prescription opioids ^b (non-prescription/non-therapeutic use)									
Other illicit opioids (specify)									

Cocaine								
Powder (salt)								
"Crack"								
Other types of cocaine (specify) ^c								
Amphetamine-type stimulants								
Amphetamine								
Methamphetamine								
"Ecstasy"-type substances								
Prescription stimulants ^d								
(non-prescription/ non-therapeutic use)								
Other illicit stimulants (specify) ^e								
Tranquilizers and sedatives								
(non-prescription/ non-therapeutic use)								
Benzodiazepines ^f								
Barbiturates ^g								
Other (specify) ^h								
Hallucinogens								
LSD								
Other hallucinogens (specify)								
Solvents and inhalants								
Other drugs such as those under national but not international control (specify)ⁱ								

^a Excluding alcohol and tobacco, but including controlled substances that are misused or used for non-therapeutic purposes.

^b Prescription opioids may include preparations containing buprenorphine, codeine, dextropropoxyphene, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone and pethidine.

^c Other types of cocaine include coca paste and cocaine paste, cocaine base, *basuco*, *paco*, *merla* etc. (based on the Multilateral Evaluation Mechanism of

the Inter-American Drug Abuse Control Commission (CICAD)).

- ^d Prescription stimulants may include preparations containing amfepramone, fenetylline, methylphenidate, pemoline, phenmetrazine and phentermine.
- ^e Other illicit amphetamine-type stimulants may include preparations such as Captagon, methcathinone, 4-MTA, 2C-B, MDBD etc.
- ^f Benzodiazepines may include preparations such as alprazolam, clonazepam, diazepam, temazepam and flunitrazepam (Rohypnol).
- ^g Barbiturates may include preparations containing allobarbitol, barbital, phenobarbital, pentobarbital, secbutabarbitol etc.
- ^h Other sedative hypnotics may include preparations containing meprobamate, methaqualone, zolpidem etc.
- ⁱ Other drugs such as those under national but not international control may include substances such as *gamma*-butyrolactone (GBL), khat, piperazines (e.g. *N*-benzylpiperazine), tramadol and ketamine.

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

Injecting drug use*

Class and type of drugs	Question									
	17			18						19
	Has there been drug use by injection in the reporting year?			What has been the trend with regard to injecting drug use in the reporting year? ^a						Has there been sharing of needles or syringes among injecting drug users in the reporting year? ^b
	No	Yes	Don't know	Large increase	Some increase	Stable	Some decrease	Large decrease	Don't know	<input type="checkbox"/> No <input type="checkbox"/> Yes <input type="checkbox"/> Don't know
Any illicit drug^c	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Opioids	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	20 What has been the trend in the sharing of needles or syringes among injecting drug users in the reporting year? ^b
Opium	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Heroin	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> Large increase <input type="checkbox"/> Some increase <input type="checkbox"/> Stable <input type="checkbox"/> Some decrease <input type="checkbox"/> Large decrease <input type="checkbox"/> Don't know
Prescription opioids ^d (non-prescription/ non-therapeutic use)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Other illicit opioids (specify)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Cocaine	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Powder (salt)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
"Crack"	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Other types of cocaine (specify) ^e	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Amphetamine-type stimulants	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Amphetamine	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Methamphetamine	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Prescription stimulants ^f (non-prescription/ non-therapeutic use)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Other illicit stimulants (specify) ^g	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Tranquilizers and sedatives (non-prescription/ non-therapeutic use)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Benzodiazepines ^h	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Barbiturates ⁱ	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Other (specify) ^j	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Other drugs such as those under national but not international control (specify)^k	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

^a "Stable" refers to an estimated variation of under 5 per cent; "some increase" and "some decrease" refer to an estimated variation of between 5 and 10 per cent; "large increase" and "large decrease" refer to an estimated variation of more than 10 per cent.

* An "injecting drug user" is a person who injects drugs for non-medical purposes.

- ^b The term “sharing needles and syringes” includes the sharing of needles, syringes and other injecting paraphernalia and practices.
- ^c For the purpose of this questionnaire, alcohol and tobacco are not included.
- ^d Prescription opioids may include preparations containing buprenorphine, codeine, dextropropoxyphene, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone and pethidine.
- ^e Other types of cocaine include coca paste and cocaine paste, cocaine base, *basuco*, *paco*, *merla* etc. (based on the Multilateral Evaluation Mechanism of the Inter-American Drug Abuse Control Commission (CICAD)).
- ^f Prescription stimulants may include preparations containing amfepramone, fenetylline, methylphenidate, pemoline, phenmetrazine and phentermine.
- ^g Other illicit amphetamine-type stimulants may include preparations such as Captagon, methcathinone, 4-MTA, 2C-B, MDBD etc.
- ^h Benzodiazepines may include preparations such as alprazolam, clonazepam, diazepam, temazepam and flunitrazepam (Rohypnol).
- ⁱ Barbiturates may include preparations containing allobarbitol, barbital, phenobarbital, pentobarbital, secbutabarbitol etc.
- ^j Other sedative hypnotics may include preparations containing meprobamate, methaqualone, zolpidem etc.
- ^k Other drugs such as those under national but not international control may include substances such as *gamma*-butyrolactone (GBL), khat, piperazines (e.g. *N*-benzylpiperazine), tramadol and ketamine.

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

Injecting drug users

21. Do you have data on the total number of injecting drug users in your country?

- ☐ No (go to question 26)
☐ Yes, for the whole country
☐ Yes, for part of country or sub-population

22. (a) In which year were the data collected? _____.

(b) Which part of the country or sub-group of the population is covered by the data? _____.

(c) What is the size of the population to which the estimates apply? _____.

(d) What is the source of the data you are reporting?

- ☐ Behavioural survey
☐ Treatment and other register of drug users
☐ Indirect estimates
☐ General population survey
☐ School survey
☐ Other (specify: _____)

Class and type of drugs	Question		
	23	24	25
	What percentage of users of each drug injects that drug?	What is the estimated number of people who inject each drug?	What percentage of injecting drug users shared needles or syringes? ^a
			Preferred time frame: last time injected Time frame used:
Any illicit drug^b			
Illicit opioids			
Heroin			
Opium			
Prescription opioids ^c			
(non-prescription/non-therapeutic use)			
Other illicit opioids (specify)			
Cocaine			
Powder (salt)			
"Crack"			
Other types of cocaine (specify) ^d			
Amphetamine-type stimulants^e			
Amphetamine			
Methamphetamine			
Prescription stimulants ^f			
(non-prescription/non-therapeutic use)			
Other illicit stimulants (specify) ^g			

Tranquilizers and sedatives

(non-prescription/non-therapeutic use)

Benzodiazepines^hBarbituratesⁱOther (specify)^j**Other drugs such as those under national
but not international control (specify)^k**

- ^a The question should ideally refer to current injecting drug users (persons who have injected drugs in the 30 days prior to responding to the questionnaire) who shared needles, syringes or other injecting paraphernalia the last time they injected.
- ^b For the purpose of this questionnaire, alcohol and tobacco are not included.
- ^c Prescription opioids may include preparations containing buprenorphine, codeine, dextropropoxyphene, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone and pethidine.
- ^d Other types of cocaine include coca paste and cocaine paste, cocaine base, *basuco*, *paco*, *merla* etc. (based on the Multilateral Evaluation Mechanism of the Inter-American Drug Abuse Control Commission (CICAD)).
- ^e Do the figures reported for use of illicit amphetamine-type stimulants include the non-prescribed/non-therapeutic use of prescription stimulants? Yes / No (circle one).
- ^f Prescription stimulants may include preparations containing amfepramone, fenetylline, methylphenidate, pemoline, phenmetrazine and phentermine.
- ^g Other illicit amphetamine-type stimulants may include preparations such as Captagon, methcathinone, 4-MTA, 2C-B, MDDC etc.
- ^h Benzodiazepines may include preparations such as alprazolam, clonazepam, diazepam, temazepam and flunitrazepam (Rohypnol).
- ⁱ Barbiturates may include preparations containing allobarbitol, barbital, phenobarbital, pentobarbital, secbutabarbitol etc.
- ^j Other sedative hypnotics may include preparations containing meprobamate, methaqualone, zolpidem etc.
- ^k Other drugs such as those under national but not international control may include substances such as *gamma*-butyrolactone (GBL), khat, piperazines (e.g. *N*-benzylpiperazine), tramadol and ketamine.

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

Severe/problem drug users*

26. Do you have data regarding the number of severe/problem drug users in your country?

- ☐ No (go to question 32)
☐ Yes, for the whole country
☐ Yes, for part of country or sub-population

27. (a) In which year were the data collected? _____.
 (b) Which part of the country or sub-group of the population is covered by the data? _____.
 (c) What definition of “severe/problem drug user” applies to the data? _____.
 (d) What was the sample size to which the data apply? _____.
 (e) What is the source of the data you are reporting?

- ☐ Behavioural survey
☐ Treatment and other register of drug users
☐ Indirect estimates
☐ General population survey
☐ School survey
☐ Other (specify: _____)

28. What is the estimated number of severe/problem drug users in your country? _____.

High-risk groups

High-risk groups	Question		
	29	30	31
	What is the estimated number of people in each high-risk group in your country?	What is the estimated annual prevalence within each group of any illicit drug use? Preferred time frame: 12 months Time frame used: _____	What is the annual prevalence of the three main drugs within each high-risk group?
Persons held in prisons ^a			1. 2. 3.
Persons in prostitution			1. 2. 3.
Homeless people			1. 2. 3.

* For the purposes of this questionnaire, “severe/problem drug users” are people who engage in the high-risk consumption of drugs, for example people who inject drugs, people who use drugs on a daily basis and/or people diagnosed as drug dependent, based on clinical criteria contained in the *International Classification of Diseases* (tenth revision) of the World Health Organization and the *Diagnostic and Statistical Manual of Mental Disorders* (fourth edition) of the American Psychiatric Association, or any similar criteria or definition that might be used.

Other high-risk groups (specify)			
			1. 2. 3.
			1. 2. 3.

^a “Persons held in prisons” are all persons held in public and privately financed institutions where persons are deprived of their liberty. These include penal, correctional, pretrial and psychiatric facilities that are part of the criminal justice system. The term does not apply to non-criminal prisoners held for administrative reasons, including persons held pending investigation into their immigration status.

Metadata
What sources of information (published and unpublished) were referred to in answering these questions?

New developments in drug use

32. Have any new drugs or new patterns of drug use been observed in the reporting year?
<input type="checkbox"/> No (go to question 35) <input type="checkbox"/> Yes
33. Which new drugs or patterns of drug use have been observed? In which population groups have these new drugs or patterns of drug use emerged?
34. Use the space below to document any other developments in the prevalence and patterns of drug use in your country over the reporting year.

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

Drug-related morbidity

Question 35

Has the prevalence of each of the infections listed below changed among injecting drug users in the reporting year?^a

Infection	Large increase	Some increase	Stable	Some decrease	Large decrease	Don't know
Hepatitis B	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Hepatitis C	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
HIV	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Tuberculosis (active)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

^a "Stable" refers to an estimated variation of under 5 per cent; "some increase" and "some decrease" refer to an estimated variation of between 5 and 10 per cent; "large increase" and "large decrease" refer to an estimated variation of more than 10 per cent.

36. Do you have an estimate of the percentage of injecting drug users with any of the infections listed in question 35?

- ☐ No (go to question 42)
- ☐ Yes, for the whole population
- ☐ Yes, for a sub-group or part of the population

37. (a) In which year were the data referred to in question 38 collected? _____.

(b) Which part of the country or sub-group of injecting drug users is covered by the estimate? _____.

(c) What was the sample size of the population to which the estimate applies? _____.

(d) What is the source of the data you are reporting?

- ☐ Behavioural survey
- ☐ Treatment and other register of drug users
- ☐ Indirect estimates
- ☐ General population survey
- ☐ School survey
- ☐ Other (specify: _____)

Infection	Question			
	38	39	40	41
	What is the estimated prevalence (%) of each infection among injecting drug users?	What is the estimated number of injecting drug users with each infection?	What is the estimated prevalence (%) of each infection among persons held in prisons?	What is the estimated number of persons held in prisons, with each infection?
Hepatitis B				
Hepatitis C				
HIV				
Tuberculosis				

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

Drug-related morbidity

42. Do you routinely collect data on the number of non-fatal drug-related consequences for health in your country?

- ☐ No (go to question 46)
☐ Yes, for the whole population
☐ Yes, for a sub-group or part of the population

43. On which consequences for health do you collect data (tick all that apply)?

- ☐ Non-fatal drug overdoses²
☐ Drug-related hospital emergency room visits³

44. (a) In which year were the data referred to in question 43 collected? _____.

(b) Which part of the country or sub-group is covered by the estimate? _____.

Consequences for health	Question
	45
	What is the number of non-fatal drug-related episodes recorded during the reporting period?
Non-fatal drug overdoses	
Drug-related hospital emergency room visits	

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

² An “overdose” is the use of any drug in such quantities as to produce acute adverse physical or mental effects. Overdoses may have transient or lasting (non-fatal) effects or result in death (see the lexicon of alcohol and drug terms of the World Health Organization, available from www.who.int/substance_abuse/terminology/who_lexicon/en).

³ “Drug-related emergency room visits” are made in cases of overdoses, for detoxification, to address withdrawal symptoms, drug-related accidents and trauma, and to treat any related mental health conditions that a drug user may present (see information of the Drug Abuse Warning Network available from <https://dawninfo.samhsa.gov>).

Drug-related mortality*

Class and type of drugs	Question								
	46		47	48					
	Have there been reports of drug-related deaths in the reporting year?		Rank these drugs in order of their importance as a primary cause of drug-related deaths	What has been the trend over the reporting year with regard to drug-related deaths? ^a					
	No	Yes		Large increase	Some increase	Stable	Some decrease	Large decrease	Don't know
Any illicit drug^b	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Cannabis	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Opioids	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Heroin/morphine	<input type="checkbox"/>	<input type="checkbox"/>							
Opium	<input type="checkbox"/>	<input type="checkbox"/>							
Prescription opioids ^c	<input type="checkbox"/>	<input type="checkbox"/>							
Other opioids (specify)	<input type="checkbox"/>	<input type="checkbox"/>							
Cocaine	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Amphetamine-type stimulants	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Amphetamine/methamphetamine	<input type="checkbox"/>	<input type="checkbox"/>							
Prescription stimulants ^d	<input type="checkbox"/>	<input type="checkbox"/>							
"Ecstasy"-type substances	<input type="checkbox"/>	<input type="checkbox"/>							
Other stimulants (specify) ^e	<input type="checkbox"/>	<input type="checkbox"/>							
Tranquilizers and sedatives	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Benzodiazepines ^f	<input type="checkbox"/>	<input type="checkbox"/>							
Barbiturates ^g	<input type="checkbox"/>	<input type="checkbox"/>							
Other sedative hypnotics (specify) ^h	<input type="checkbox"/>	<input type="checkbox"/>							
Hallucinogens	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Solvents and inhalants	<input type="checkbox"/>	<input type="checkbox"/>	<input type="text"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

* "Drug-related mortality" refers to deaths directly or indirectly caused by the intake of illicit drugs and psychotropic substances. The use of illicit drugs and psychotropic substances can lead indirectly to deaths in cases of drug-induced violence and traffic accidents. The standards used for recording drug-related deaths or mortality may include ICD 10 or a country's own definitions and practices.

Other drugs such as those under national but not international control (specify)ⁱ

	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

^a “Stable” refers to an estimated variation of under 5 per cent; “some increase” and “some decrease” refer to an estimated variation of between 5 and 10 per cent; “large increase” and “large decrease” refer to an estimated variation of more than 10 per cent.

^b For the purpose of this questionnaire, alcohol and tobacco are not included.

^c Prescription opioids may include preparations containing buprenorphine, codeine, dextropropoxyphene, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone and pethidine.

^d Prescription stimulants may include preparations containing amfepramone, fenetylline, methylphenidate, pemoline, phenmetrazine and phentermine.

^e Other illicit amphetamine-type stimulants may include preparations such as Captagon, methcathinone, 4-MTA, 2C-B, MDBD etc.

^f Benzodiazepines may include preparations such as alprazolam, clonazepam, diazepam, temazepam and flunitrazepam (Rohypnol).

^g Barbiturates may include preparations containing allobarbitol, barbitol, phenobarbitol, pentobarbitol, secbutabarbitol etc.

^h Other sedative hypnotics may include preparations containing meprobamate, methaqualone, zolpidem etc.

ⁱ Other drugs such as those under national but not international control may include substances such as *gamma*-butyrolactone (GBL), khat, piperazines (e.g. *N*-benzylpiperazine), tramadol and ketamine.

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

Drug-related mortality

49. Do you have data regarding the number of drug-related deaths in your country?

- ☐ No (go to question 54)
☐ Yes, for the whole population
☐ Yes, for a sub-group or part of the population

50. (a) In which year were the data referred to in question 49 collected? _____.

(b) Which part of the country or sub-group of the population is covered by the data? _____.

(c) What is the size of the reference population to which the data apply? _____.

Class and type of drugs	Question		
	51	52	53
	What is the total number of drug-related deaths? ^a	What is the number of fatal drug overdoses? ^b	What is the number of drug-related HIV/AIDS deaths? ^c
Any illicit drug^d			
Cannabis			
Opioids			
Heroin/morphine			
Opium			
Prescription opioids ^e			
Other opioids (specify)			
Cocaine			
Amphetamine-type stimulants			
Amphetamine/methamphetamine			
Prescription stimulants ^f			
"Ecstasy"-type substances			
Other stimulants (specify) ^g			
Tranquilizers and sedatives			
Benzodiazepines ^h			
Barbiturates ⁱ			
Other sedative hypnotics (specify) ^j			
Hallucinogens			
Solvents and inhalants			
Other drugs such as those under national but not international control (specify)^k			
54. What proportion of these deaths were for polydrug use?			

^a "Drug-related mortality" refers to deaths directly or indirectly caused by the intake of illicit drugs and psychotropic substances. The use of illicit drugs and psychotropic substances can lead indirectly to deaths in cases of drug-induced violence and traffic accidents. The standards used for recording drug-related deaths or mortality may include the *International Classification of Diseases* (tenth revision) of the World Health Organization or a country's own definitions and practices.

^b In a "fatal drug overdose", an overdose or drug intoxication has been assessed as being the direct underlying cause of death. Such cases can be identified from general mortality registers based on the *International Classification of Diseases* (tenth revision) of the World Health Organization or a similar classification system, or from special mortality registers (if they include drug overdoses as a separate category), whichever system is applicable to a given country.

^c In a “drug-related HIV/AIDS death”, HIV/AIDS has been assessed as the direct underlying cause of death and injecting drugs has been identified as the mode of transmission of HIV.

^d For the purpose of this questionnaire, alcohol and tobacco are not included.

^e Prescription opioids may include preparations containing buprenorphine, codeine, dextropropoxyphene, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone and pethidine.

^f Prescription stimulants may include preparations containing amfepramone, fenetylline, methylphenidate, pemoline, phenmetrazine and phentermine.

^g Other illicit amphetamine-type stimulants may include preparations such as Captagon, methcathinone, 4-MTA, 2C-B, MDDC etc.

^h Benzodiazepines may include preparations such as alprazolam, clonazepam, diazepam, temazepam and flunitrazepam (Rohypnol).

ⁱ Barbiturates may include preparations containing allobarbitol, barbitol, phenobarbitol, pentobarbitol, secbutabarbitol etc.

^j Other sedative hypnotics may include preparations containing meprobamate, methaqualone, zolpidem etc.

^k Other drugs such as those under national but not international control may include substances such as *gamma*-butyrolactone (GBL), khat, piperazines (e.g. *N*-benzylpiperazine), tramadol and ketamine.

Criteria

What international or national criteria have been used to define drug-related mortality in the country?

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

Drug treatment*

Class of drugs	Question									
	55		56		57					
	Have people received treatment for problems with this class of drugs in the reporting year?		Rank these drugs in order of their importance as the primary reason for receiving treatment.		Has there been any change in the number of people receiving treatment for each drug? ^a					
	No	Yes			Large increase	Some increase	Stable	Some decrease	Large decrease	Don't know
Any illicit drug (total)^b	<input type="checkbox"/>	<input type="checkbox"/>			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Cannabis	<input type="checkbox"/>	<input type="checkbox"/>			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Opioids	<input type="checkbox"/>	<input type="checkbox"/>			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Cocaine	<input type="checkbox"/>	<input type="checkbox"/>			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Amphetamine-type stimulants	<input type="checkbox"/>	<input type="checkbox"/>			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Sedatives and tranquilizers	<input type="checkbox"/>	<input type="checkbox"/>			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Hallucinogens	<input type="checkbox"/>	<input type="checkbox"/>			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Solvents and inhalants	<input type="checkbox"/>	<input type="checkbox"/>			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other drugs such as those under national but not international control (specify)^c										
_____	<input type="checkbox"/>	<input type="checkbox"/>			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
_____	<input type="checkbox"/>	<input type="checkbox"/>			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
_____	<input type="checkbox"/>	<input type="checkbox"/>			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

^a “Stable” refers to an estimated variation of under 5 per cent; “some increase” and “some decrease” refer to an estimated variation of between 5 and 10 per cent; “large increase” and “large decrease” refer to an estimated variation of more than 10 per cent.

^b For the purpose of this questionnaire, alcohol and tobacco are not included.

^c Other drugs such as those under national but not international control may include substances such as *gamma*-butyrolactone (GBL), khat, piperazines (e.g. *N*-benzylpiperazine), tramadol and ketamine.

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

* “Drug treatment” is any structured intervention aimed specifically at addressing a person’s drug use, including stabilization or reduction of drug use, maintenance or abstinence regimes, behavioural therapy, medical or psychological interventions etc.

Drug treatment

58. Do you have any data regarding the number of people receiving drug treatment in your country?

- ☐ No (go to question 67)
☐ Yes, for the whole country
☐ Yes, for part of the country or some treatment facilities

59. (a) In which year were the data referred to in question 58 collected? _____.

(b) Which part of the country or what types of treatment facilities are covered by the data? _____.

Note: Questions 60-63 refer to the year specified in question 59 (a).

Class and type of drugs	Question			
	60	61	62	63
	What is the estimated number of people who received drug treatment? ^a	What percentage of people in drug treatment entered treatment for the first time ever?	What percentage of people in drug treatment are female?	What is the median age of people in drug treatment?
Any illicit drug (total)^b				
Primary drug^c				
Cannabis				
Opioids				
Heroin				
Opium				
Prescription opioids (non-prescription/non-therapeutic use) ^d				
Other illicit opioids (specify)				
Cocaine				
Other types of cocaine (specify) ^e				
Amphetamine-type stimulants				
Methamphetamine				
Amphetamine				
"Ecstasy"-type substances				
Prescription stimulants (non-prescription/non-therapeutic use) (specify) ^f				
Tranquilizers and sedatives				
Benzodiazepines ^g				
Barbiturates ^h				

Others sedative hypnotics (specify) ⁱ				
Hallucinogens				
LSD				
Other hallucinogens (specify)				
Solvents and inhalants				
Other drugs such as those under national but not international control (specify)^j				
What proportion of people were treated for polydrug use?				

^a In this question, the numbers should refer to individuals who have received treatment and who would normally be included in national reporting requirements.

^b For the purpose of this questionnaire, alcohol and tobacco are not included.

^c The “primary drug” is the main drug used by a person and for which he or she is seeking drug treatment.

^d Prescription opioids may include preparations containing buprenorphine, codeine, dextropropoxyphene, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone and pethidine.

^e Other types of cocaine include coca paste and cocaine paste, cocaine base, *basuco*, *paco*, *merla* etc. (based on the Multilateral Evaluation Mechanism of the Inter-American Drug Abuse Control Commission (CICAD)).

^f Prescription stimulants may include preparations containing amfepramone, fenetylline, methylphenidate, pemoline, phenmetrazine and phentermine.

^g Benzodiazepines may include preparations such as alprazolam, clonazepam, diazepam, temazepam and flunitrazepam (Rohypnol).

^h Barbiturates may include preparations containing allobarbitol, barbitol, phenobarbital, pentobarbital, secbutabarbitol etc.

ⁱ Other sedative hypnotics may include preparations containing meprobamate, methaqualone, zolpidem etc.

^j Other drugs such as those under national but not international control may include substances such as *gamma*-butyrolactone (GBL), khat, piperazines (e.g. *N*-benzylpiperazine), tramadol and ketamine.

64. Does the total number of people in treatment provided above include people in treatment for alcohol abuse?

- ☐ Yes. Please specify the total number of people in treatment for alcohol abuse: _____.
- ☐ No

65. What is the estimated proportion of drug users in need of treatment that is currently receiving treatment in your country?

- ☐ None or almost none
- ☐ A minority
- ☐ About half
- ☐ The majority
- ☐ All or almost all
- ☐ Don't know

Definitions	Question
	66
	What definition of “people in drug treatment” applies to the responses provided to questions 59-63? ^a
All people receiving treatment in the reporting year	<input type="checkbox"/>
People starting treatment in the reporting year	<input type="checkbox"/>
People in treatment at census date	<input type="checkbox"/>
People discharged from treatment	<input type="checkbox"/>
Other (specify)	<input type="checkbox"/>

^a Check all that apply.

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

Collecting data and monitoring capacity

Registers, surveys and rapid situation assessments	Question				
	67				
(a) Does your country collect the following data regarding drug use and treatment?					
	No	Yes			
Registers					
National data on drug treatment	<input type="checkbox"/>	<input type="checkbox"/>			
Register of all drug users	<input type="checkbox"/>	<input type="checkbox"/>			
Register of problem drug users	<input type="checkbox"/>	<input type="checkbox"/>			
Register on drug-related morbidity	<input type="checkbox"/>	<input type="checkbox"/>			
Register on drug-related mortality	<input type="checkbox"/>	<input type="checkbox"/>			
(b) How often does your country carry out the following data collection activities regarding drug use and its health and social consequences?					
	Never	Once a year	Every two years	Every three to five years	Every six or more years
Surveys					
General population survey	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
School population survey	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Survey among drug users	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Survey among prisoners	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Indirect estimates	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Rapid situation assessments	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other data collections (specify)					
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Registers, surveys and rapid situation assessments	Question		
	68		
How suitable do you think the following data sources are for estimating the drug situation in your country?			
	Not very	Somewhat	Very
Registers			
National data collection on drug treatment	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Register of problem drug users	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Register on drug-related morbidity	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Register on drug-related mortality	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Surveys			
General population survey	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
School population survey	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Survey among drug users	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Survey among prisoners	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Indirect estimates	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Rapid situation assessments	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other data collections (specify)			
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

69. What measures (if any) have been taken to improve data collection systems for monitoring drug use at the national level in your country? What are the main barriers to implementing improved data collection systems?

70. Does your country have a national body dedicated to monitoring the situation with regard to illicit drugs?

- ☐ Yes
☐ No

Metadata

What sources of information (published and unpublished) were referred to in answering these questions?

Additional comments

Use the space below to make notes and comments, to clarify any information contained in this questionnaire and to document any other issues that you wish to draw to the attention of UNODC. If your comment relates to a specific question in the questionnaire, please refer to the corresponding question number.